New hope for Long-Term control of rare swelling disorder
NCT ID NCT07204938
Summary
This study aims to evaluate the long-term safety and effectiveness of navenibart for people with hereditary angioedema (HAE), a rare condition causing sudden, severe swelling. The trial involves 145 adults and adolescents who previously participated in an earlier study of the same medication. Participants will receive navenibart, with the option for personalized dosing based on individual needs, to see how well it controls attacks over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 2
Scottsdale, Arizona, 85251, United States
Conditions
Explore the condition pages connected to this study.